BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Dr. Drew Responds to News He Was Paid by GlaxoSmithKline (GSK)


7/5/2012 7:49:40 AM

One of the bits of information that came out of GlaxoSmithKline's $3 billion settlement with the government over drug marketing practices was that media personality Dr. Drew Pinsky took $275,000 from the company at the same time he was talking up its antidepressant Wellbutrin back in the 1990s, the Wall Street Journal reports.

Pinsky told listeners during his "Loveline" radio show the drug "may enhance or at least not suppress sexual arousal" like other antidepressants, the Journal said. The label on the drug made no such claim. "My comments were consistent with my clinical experience," Pinsky told the Journal. He acknowledged receiving payments from GlaxoSmithKline (NYSE:GSK) predecessor Glaxo Wellcome for "a two-year initiative discussing intimacy and depression."

Part of the last week's settlement concerned "allegations that the company plied doctors with cash and lavish trips to resorts to get them to promote Glaxo drugs for uses beyond those specified in the drugs' FDA-approved prescribing labels," the report noted.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->